What happens when a new drug comes charging out of the launch gate? For Biogen Idec ($BIIB), it means a rethink of its real estate plans. Its fast-growing staff won't all fit in the new headquarters under construction in Cambridge, MA. Report
For innovative pharmaceutical companies, opportunities for new pharmaceutical products exist within the products, patents, technologies and intellectual properties they already own or control. For these companies, and also for generic companies that are looking for alternative revenue sources to offset losses caused by the generic cliff, the 505(b)(2) pathway offers great potential. Learn more here.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!